In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
News|Podcasts|January 7, 2026
ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & Johnson’s positive Phase IIb results for nipocalimab in systemic lupus erythematosus, and break down a new multibillion-dollar research and licensing agreement between Nimbus Therapeutics and Eli Lilly targeting oral obesity treatments.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In the fifth and final part of our video interview series, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American Cancer Society,
discusses the structural challenges limiting representative enrollment in US cancer trials. Sivendran highlights how trials conducted largely outside the US or concentrated in urban centers can fail to reflect the populations most affected by specific cancers, citing EGFR-positive lung cancer as an example where enrollment must align with disease epidemiology to support regulatory approval and meaningful innovation. - Johnson & Johnson
reported positive Phase IIb results from the JASMINE trial evaluating nipocalimab in adults with systemic lupus erythematosus. The 52-week, randomized, double-blind, placebo-controlled study met its primary endpoint at 24 weeks and achieved key secondary and exploratory endpoints, including signals supporting steroid-sparing potential. J&J stated the safety and tolerability profile was consistent with prior studies and plans to present full results at a future medical conference. - Nimbus Therapeutics
announced a multi-year research collaboration and exclusive license agreement with Eli Lilly to develop oral therapies for obesity and metabolic disease. Under the agreement, Nimbus will receive upfront and near-term milestone payments totaling $55 million, with eligibility for up to $1.3 billion in development and commercial milestones, along with tiered royalties. The collaboration builds on a prior partnership and combines Nimbus’ computational drug design capabilities with Lilly’s metabolic disease development expertise.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine three priorities for first-time APAC sponsors, how continuous glucose monitoring should be used in diabetes trials, and why FDA is requiring a new eye-related warning across GLP-1 medications.
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
In today’s ACT Brief, we examine how China’s trial startup timelines compare with those in the US and Europe, whether AI-drafted clinical study reports speed drug development, and how Bimzelx compared with Skyrizi in psoriatic arthritis.
In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.
In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.
In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
Trending on Applied Clinical Trials Online
1
FDA Reportedly Pauses Commissioner’s National Priority Voucher Pilot as Existing Reviews Continue
2
How Inconsistent Screening Shapes Which Oncology Patients Get Flagged for Trials
3
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
4
What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial
5